Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 7
2003 4
2004 2
2005 3
2006 2
2007 6
2008 7
2009 3
2010 6
2011 18
2012 16
2013 16
2014 17
2015 8
2016 4
2017 10
2018 12
2019 12
2020 20
2021 22
2022 15
2023 17
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

209 results

Results by year

Filters applied: . Clear all
Page 1
Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial.
Wei AH, Montesinos P, Ivanov V, DiNardo CD, Novak J, Laribi K, Kim I, Stevens DA, Fiedler W, Pagoni M, Samoilova O, Hu Y, Anagnostopoulos A, Bergeron J, Hou JZ, Murthy V, Yamauchi T, McDonald A, Chyla B, Gopalakrishnan S, Jiang Q, Mendes W, Hayslip J, Panayiotidis P. Wei AH, et al. Among authors: yamauchi t. Blood. 2020 Jun 11;135(24):2137-2145. doi: 10.1182/blood.2020004856. Blood. 2020. PMID: 32219442 Free PMC article. Clinical Trial.
[Overview].
Yamauchi T. Yamauchi T. Rinsho Ketsueki. 2021;62(6):560-561. doi: 10.11406/rinketsu.62.560. Rinsho Ketsueki. 2021. PMID: 34219081 Japanese. No abstract available.
[Ⅲ. Bcl-2 Inhibitor in AML Therapy].
Hosono N, Yamauchi T. Hosono N, et al. Among authors: yamauchi t. Gan To Kagaku Ryoho. 2022 May;49(5):545-548. Gan To Kagaku Ryoho. 2022. PMID: 35578931 Japanese. No abstract available.
Clinical utility of genomic profiling of AML using paraffin-embedded bone marrow clots: HM-SCREEN-Japan 01.
Hosono N, Chi S, Yamauchi T, Fukushima K, Shibayama H, Katagiri S, Gotoh A, Eguchi M, Morishita T, Ogasawara R, Kondo T, Yanada M, Yamamoto K, Kobayashi T, Kuroda J, Usuki K, Utsu Y, Yoshimitsu M, Ishitsuka K, Ono T, Takahashi N, Iyama S, Kojima K, Nakamura Y, Fukuhara S, Izutsu K, Abutani H, Yamauchi N, Yuda J, Minami Y; All HM-SCREEN-Japan 01 Investigators. Hosono N, et al. Among authors: yamauchi t. Cancer Sci. 2023 May;114(5):2098-2108. doi: 10.1111/cas.15746. Epub 2023 Mar 1. Cancer Sci. 2023. PMID: 36793248 Free PMC article.
Mutated KIT Tyrosine Kinase as a Novel Molecular Target in Acute Myeloid Leukemia.
Katagiri S, Chi S, Minami Y, Fukushima K, Shibayama H, Hosono N, Yamauchi T, Morishita T, Kondo T, Yanada M, Yamamoto K, Kuroda J, Usuki K, Akahane D, Gotoh A. Katagiri S, et al. Among authors: yamauchi t. Int J Mol Sci. 2022 Apr 23;23(9):4694. doi: 10.3390/ijms23094694. Int J Mol Sci. 2022. PMID: 35563085 Free PMC article. Review.
Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trial.
Roboz GJ, Sanz G, Griffiths EA, Yee K, Kantarjian H, Récher C, Byrne MT, Patkowska E, Kim HJ, Thomas X, Moors I, Stock W, Illés Á, Fenaux P, Miyazaki Y, Yamauchi T, O'Connell CL, Hao Y, Keer HN, Azab M, Döhner H. Roboz GJ, et al. Among authors: yamauchi t. Blood Adv. 2024 Apr 23;8(8):2020-2029. doi: 10.1182/bloodadvances.2023012062. Blood Adv. 2024. PMID: 38231126 Clinical Trial.
Ewing sarcoma with very late metastasis in the skull: a case report.
Hagihara R, Arishima H, Yamauchi T, Kawajiri S, Ito T, Fukushima M, Kikuta K. Hagihara R, et al. Among authors: yamauchi t. J Med Case Rep. 2022 Nov 15;16(1):419. doi: 10.1186/s13256-022-03656-5. J Med Case Rep. 2022. PMID: 36376967 Free PMC article. Review.
209 results